Drug Insights

Is Fenfluramine approved by the FDA?

3 July 2024
3 min read

Yes, fenfluramine (brand name: Fintepla) is FDA approved. The U.S. Food and Drug Administration (FDA) approved fenfluramine on June 25, 2020, for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.

What is Fenfluramine?

Fenfluramine is an oral medication used to treat seizures caused by Dravet syndrome and Lennox-Gastaut syndrome in patients who are at least 2 years old. These conditions are severe forms of epilepsy that begin in infancy or early childhood and are characterized by frequent, prolonged, and often treatment-resistant seizures.

How Does Fenfluramine Work?

Fenfluramine is classified under drug classes such as anorexiants, CNS stimulants, and miscellaneous anticonvulsants. It works by affecting serotonin levels in the brain, which can help reduce the frequency and severity of seizures.

Usage and Administration

Fenfluramine is available in oral solution form with a concentration of 2.2 mg/mL. The dosage and administration of fenfluramine must be carefully managed by a healthcare provider due to the risk of serious side effects.

Dosage:

  • The specific dosage depends on the patient's weight and the severity of the condition.
  • The medication can be taken with or without food.
  • It's essential to measure the liquid medicine carefully using the provided dosing syringe or a medicine dose-measuring device.

Monitoring:

  • Regular monitoring of heart function using an electrocardiograph (ECG) is required due to the risk of cardiac side effects.
  • Patients should be weighed regularly, as fenfluramine can cause decreased appetite and weight loss, which may affect growth in children.

Precautions and Considerations

Before Treatment:

  • Patients should not use fenfluramine if they have used an MAO inhibitor in the past 14 days due to the risk of dangerous drug interactions.
  • Inform your doctor if you have a history of heart problems, weight loss, depression, suicidal thoughts, drug or alcohol addiction, liver, or kidney disease.
  • Pregnant women should avoid using fenfluramine, and effective birth control should be used during treatment and for a period after the last dose.

Warnings:

  • Fenfluramine can cause serious side effects on the heart and lungs, including chest pain, shortness of breath, and swelling in the lower legs.
  • The medication may also affect mood and behavior, potentially leading to anxiety, panic attacks, or suicidal thoughts.

Side Effects

Common Side Effects:

  • Increased blood pressure
  • Drowsiness
  • Decreased weight
  • Loss of appetite, vomiting, diarrhea, constipation
  • Seizures that do not stop
  • Feeling weak or tired
  • Fever, infections
  • Abnormal heart function tests
  • Problems with balance, walking, or muscle movement
  • Drooling
  • Cold symptoms such as stuffy nose, sneezing, sore throat

Serious Side Effects:

  • Serious heart and lung issues
  • Suicidal thoughts and behavior changes
  • Serotonin syndrome symptoms (agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness)

Conclusion

Fenfluramine (Fintepla) received FDA approval on June 25, 2020, for treating seizures associated with Dravet syndrome in patients aged 2 years and older. It is a significant treatment option for managing this severe form of epilepsy, though it requires careful monitoring and management due to potential serious side effects. Always consult with a healthcare provider for personalized medical advice and follow all prescribed guidelines for safe use.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Elevation Oncology Reveals EO-3021 Strategy for Gastric Cancer Patients
Latest Hotspot
3 min read
Elevation Oncology Reveals EO-3021 Strategy for Gastric Cancer Patients
3 July 2024
Elevation Oncology Unveils New Strategy for EO-3021 in Gastric and Gastroesophageal Junction Cancer Patients.
Read →
Is Lurbinectedin approved by the FDA?
Drug Insights
3 min read
Is Lurbinectedin approved by the FDA?
3 July 2024
The U.S. Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin on June 15, 2020.
Read →
Bicara Therapeutics Reveals New Phase 1/1b Results for Ficerafusp Alfa in HPV-negative Recurrent/Metastatic HNSCC
Latest Hotspot
3 min read
Bicara Therapeutics Reveals New Phase 1/1b Results for Ficerafusp Alfa in HPV-negative Recurrent/Metastatic HNSCC
2 July 2024
Bicara Therapeutics Announces New Interim Phase 1/1b Data for Ficerafusp Alfa (BCA101) in First-Line HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 2
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 2
2 July 2024
Jul 2nd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.